S the early description of periarteritis nodosa by Kussmaul and Maier in 1866 [1] , authors have attempted to develop systems for the nomenclature and classification of the vasculitides. The most widely accepted of these have usually included consideration of the size of vessel predominantly involved and the histological appearance on biopsy [2, 3] . Recently, two new systems have been proposed which broadly utilize the above principles. The 1990 American College of Rheumatology (ACR) criteria for the classification of vasculitis were derived from analysis of a large series of cases of systemic vasculitis [4] . Criteria with the highest discriminating value were used to distinguish one syndrome from another. This set tends to rely on clinical features and simple adjunctive tests with the aim of providing a framework for comparative studies between centres [4] . The 1992 Chapel Hill Consensus Conference sought to propose absolute pathological definitions of each disease considered [5] . As such, they chiefly rely on histological parameters to distinguish diseases. Since these two systems have begun to be widely adopted, it was the aim of this study to apply them in the same group of patients with primary systemic vasculitis in order to assess their relative usefulness in routine clinical practice, and also to identify the areas of agreement and divergence between them.
PATIENTS AND METHODS

Patients
We recruited patients with primary systemic vasculitis, i.e. an illness with symptoms or signs of vasculitis affecting two or more organs without any identifiable underlying cause, from rheumatology, nephrology and immunology clinics in the greater Belfast area, who first presented or who had their most recent relapse between August 1990 and July 1994. Patients were included who had biopsy evidence of vasculitis or necrotizing and crescentic glomerulonephritis (NCGN). In the absence of biopsy evidence, we included patients who had an illness affecting two or more organ systems in a clinical pattern typical of a vasculitic syndrome, which was associated with high-titre (q1/80) antineutrophil cytoplasmic antibodies (ANCA). In addition, all the 'biopsy-negative' patients had responded to immunosuppressive therapy at the time of review. We excluded patients who had insufficient evidence to sustain the diagnosis of vasculitis in the absence of a definite biopsy diagnosis, patients with single-organ vasculitis and those with large-vessel vasculitis, i.e. Takayasu arteritis or giant cell arteritis. The upper and lower respiratory tracts were assessed as two distinct organ systems in this study.
Diagnostic classification of patients
All patients had a history and clinical examination performed, and clinical features were recorded on a standardized proforma. Their case notes were also reviewed and additional clinical features and laboratory data on all patients were recorded during the course of their initial illness and subsequent follow-up. Patients were first classified according to the 1990 ACR criteria (traditional format) as polyarteritis nodosa (ACR-PAN) [6] , Wegener's granulomatosis (ACR-WG) [7] , Churg-Strauss syndrome (ACR-CSS) [8] , or unclassified (ACR-UN) in which there were insufficient of the above classification features present. We then applied the 1992 Chapel Hill Consensus Conference definitions to all patients, who were therefore defined as polyarteritis nodosa (CHCC-PAN), microscopic polyangiitis (CHCC-MPA), Wegener's granulomatosis (CHCC-WG), Churg-Strauss syndrome (CHCC-CSS) or undefined (CHCC-UN) [5] .
Antineutrophil cytoplasmic antibody testing
ANCA were detected by indirect immunofluorescence (IIF) [9] , a titre of e1/40 was taken as positive. Myeloperoxidase (MPO) antibodies were measured using a commercially available ELISA (Biocarb Diagnostics AB Sweden) (normal Q 20%). Testing for antibodies to proteinase 3 (PR3) was not available in Belfast during the period of this study, we therefore retrospectively tested serum from the time of diagnosis or relapse, where available, using a commercially available ELISA [Diatstat anti-PR3 (cANCA) kit, Shield Diagnostics Ltd, Dundee] (normal Q 2.0 U/ml).
RESULTS
Clinical features
We studied 24 patients who fulfilled the inclusion criteria for primary systemic vasculitis, 17 males and seven females, median age 49 yr (range 26-80 yr). Eleven patients initially described a prodromal illness lasting 1-12 weeks (median 6 weeks) prior to the onset of specific symptoms for which they sought medical advice. This was characterized by non-specific symptoms including malaise, anorexia, weight loss, night sweats, myalgia and arthralgia. Initial presenting features were upper respiratory tract (7), cutaneous (5), musculoskeletal (4), lower respiratory tract (3), neurological (1), ophthalmic (1), macroscopic haematuria (1), and two patients had an increased creatinine noted after a non-specific prodromal illness. During the course of illness, the commonest systems involved were musculoskeletal (18), skin (17), upper respiratory tract (17), lower respiratory tract (17) and kidney (15) .
Investigations at diagnosis or relapse
Nineteen patients had ANCA detected (18 cANCA, one pANCA) ( Table I) . Three patients had positive MPO antibodies, two cANCA and the other pANCA pattern on IIF. Sera for PR3 testing were available from 18 patients, 15 of whom were positive (Table I ). All patients with positive PR3 had a cANCA pattern on IIF. Fourteen (93%) subsequently classified as ACR-WG had cANCA and one was negative on repeated testing, 12 of 13 (92%) ACR-WG tested had positive PR3 and one had positive MPO antibodies. None of 14 patients investigated had hepatitis B surface antigen detected. Two patients had normal visceral angiography and one patient had retinal vasculitis confirmed by fluorescein angiography.
Biopsy details
Thirty-seven biopsies were performed on 22 patients. Vasculitis was found in 19 biopsies from 17 patients, two other patients had NCGN (Fig. 1) . In these 19 patients with vasculitis or NCGN on biopsy, eight also had biopsy evidence of perivascular granulomatous inflammation and three had eosinophil-rich perivascular inflammation seen, although not always on the same biopsy. Of the five patients without biopsy evidence of vasculitis or NCGN, two had no biopsies performed, two had non-specific features seen and one had a biopsy of the upper respiratory tract showing perivascular granulomatous inflammation but no vasculitis. The clinical data and supportive investigations of these 'biopsy-negative' patients are summarized in Table II .
Comparison of the ACR 1990 criteria and the Chapel Hill Consensus 1992 definitions (Appendix)
As stated, our primary comparisons were made with reference to the ACR classification (e.g. ACR-WG) (Table III) . By the ACR criteria, 15 patients were classified as WG, four had CSS, two had PAN and three were unclassified. One patient with CSS would also have fulfilled the criteria for WG; however, the dominant features of the illness were more in keeping with CSS. Of the 15 patients classified as WG, seven had granulomatous inflammation documented on biopsy. The application of the CHCC definitions is summarized below.
ACR-WG. Of these 15 patients, seven had granulomatous inflammation on biopsy, one of which was outside the respiratory tract (urethra), and one had no associated vasculitis seen. Five, therefore, could be defined as CHCC-WG, the other two remained undefined (CHCC-UN). Five patients had pauci-immune necrotizing vasculitis without evidence of granulomata and therefore would satisfy the definition of microscopic polyangiitis (CHCC-MPA). Three had no biopsy and were therefore undefined (CHCC-UN).
ACR-CSS. All patients had asthma and blood eosinophilia (q10% on differential white cell count) [8] . Three had biopsies performed which showed eosinophil-rich inflammation with necrotizing vasculitis, two of which also showed eosinophilic granulomata. However, none of these were from the respiratory tract [skin (1), mesentery (1) and lower urinary tract (1)]; thus, no patient could be defined as CHCC-CSS. The patient without biopsy also remains undefined (CHCC-UN) .
ACR-PAN. Both these patients had pauci-immune vasculitis of arterioles and venules, and therefore were defined as CHCC-MPA. PAN. Another had pauci-immune small vessel vasculitis, i.e. CHCC-MPA, and one had pauci-immune NCGN but no biopsy evidence of granulomata, a systemic illness and serous otitis media which we considered as 'probable' CHCC-MPA [5] . Therefore, of 24 patients, five were defined as CHCC-WG, eight as CHCC-MPA, one as probable CHCC-MPA, one as CHCC-PAN and nine remained undefined. Only five patients were concordant for both terms, all of whom had WG (Table III) .
DISCUSSION
We have found significant discordance between these two recently proposed systems for the nomenclature of primary systemic vasculitis. The clinicopathological features of this group of patients have been well characterized and 80% had biopsy support for the diagnosis, which is comparable to other larger series of similar patients [10] . We felt that the clinical and investigative features of the five patients without biopsy confirmation were sufficient to warrant their inclusion in this study. A biopsy is not always necessary to apply the ACR criteria [11] and we were able to classify all our 'biopsy-negative' cases by this system. Our inclusion of such cases serves to illustrate an important difference in these two criteria sets and also reflects the practical setting in which these diseases are encountered. Systemic vasculitides often develop in a staged manner [12, 13] and established histological criteria may be difficult to satisfy in the initial phase of the illness when prompt therapy is necessary [12, 13] .
F. 1.-Number and outcome of biopsies taken, by site, in patients with systemic vasculitis. GIT, gastrointestinal tract; Ureth., urethra; Musc., muscle.
ACR-Unclassified. All three of these had biopsies, one of which showed arteritis in the kidney without glomerulonephritis and could be defined as CHCC- On comparing these two systems, we found that for 24 patients, the two systems were only in agreement in five cases. The apparent discrepancies are, however, not surprising since we are not strictly speaking comparing like with like. The Chapel Hill Consensus Conference aimed to define particular diagnostic entities by proposing what abnormalities in a patient warrant the assignment of a particular diagnostic term [5] . As such, they chiefly rely on histological features. The complete set of defining features is difficult to demonstrate in routine clinical practice and we were only able confidently to assign 14 (58%) of our cohort to a CHCC definition. The ACR, on the other hand, have provided a framework in which a particular patient can be classified into a consistent category on the basis of clinicopathological features for the purposes of comparative studies [4] . Classification criteria tend to focus on manifestations which are characteristic of a syndrome, as opposed to diagnostic criteria that include features which, although typical of a condition, may also be seen in other similar conditions [4] . What is now required are validated clinical and laboratory surrogates which accurately correlate with the defining histological process and will serve as diagnostic criteria to satisfy the CHCC definition. With regard to specific differences in these systems, it is our impression that the ACR criteria overclassified WG, principally because MPA is not identified as a separate entity. Therefore, all patients with pulmonary-renal syndromes are included in the WG group simply on the basis of this clinical presentation. Not all patients with this syndrome have a granulomatous vasculitis [5] and it is, therefore, not surprising that we were able to define 5/15 patients with ACR-WG as CHCC-MPA. It has been suggested that ANCA testing aids this differentiation as cANCA and, in particular, PR3 antibodies have been found to be highly sensitive and specific for WG [14] . We found that cANCA was closely associated with ACR-WG, for which it had a sensitivity and specificity of 93 and 56%, respectively, compared to the other vasculitides in our series (Table I) . Testing for PR3 antibodies yielded a similar sensitivity and specificity of 92 and 60%, respectively; the specificity for ACR-WG may, however, be higher as serum from several non-WG patients was not available for study. Conversely, since five of our 15 ACR-WG patients could be defined as having CHCC-MPA, the specificity of PR3 for WG may be lower than currently reported. Further study is therefore necessary, using pre-agreed criteria for a particular syndrome, to assess accurately whether ANCA can be used as a surrogate for biopsy and, in particular, their utility in differentiating granulomatous and non-granulomatous vasculitis. We also had two patients with granulomatous inflammation who remained undefined by the CHCC definitions. Both these patients had ACR-WG which spared the kidneys. The CHCC did not seek to address this particular group [5] ; however, since WG and its 'limited' variants form part of the spectrum of one disease [12] , it would seem logical to attempt to arrive at a definition of WG which will include the whole spectrum of this single disease.
Three of our patients with ACR-CSS had biopsies which contained most of the requisite histological features to sustain the diagnosis; however, none had respiratory tract histology as required in the CHCC definition. All patients did, however, fulfil Lanham's [13] clinical criteria for the diagnosis of CSS which again underlines the need for surrogates for the defining features to complement the CHCC definition.
Whether similar histological features at other sites is an adequate surrogate in CSS should be studied further. Of the three patients unclassified by the ACR criteria, two could be confidently given a CHCC definition. The fact that two of these probably had MPA emphasizes its lack of recognition by the ACR classification system. We also note one patient in this series with arterial involvement only on renal biopsy. Visceral angiography was not performed and no evidence of glomerulonephritis was found. It is likely that this is a case of PAN as defined by the Chapel Hill definition. If one accepts the proposed differentiation of PAN and MPA, it illustrates how uncommon this 'classical' variant of PAN is in modern series of vasculitis as only one of our 24 patients and none of a recently reported series of 130 patients fulfilled this definition [15] . The apparent rarity of classical PAN may, however, be an artefact of a highly exclusive definition of PAN proposed by the CHCC, indeed both our ACR-PAN patients were defined as CHCC-MPA. Others who have studied the characteristics of these two conditions suggest that the CHCC definition of MPA may itself be overinclusive and that two separate patterns of disease exist within the 'polyarteritis' group which do have important differences with regard to clinical expression, ANCA status and course [16] .
We have, therefore, found significant discordance between two recently proposed systems for the nomenclature of primary systemic vasculitis. The criteria set applied should, therefore, be taken note of in any future studies reported. The ACR 1990 criteria tend to over-classify patients as WG, mainly because they do not identify MPA as a separate entity. The 1992 Chapel Hill definitions are limited in their practical use as they are biopsy dependent, the data from which are often limited to specific sites and stages of the disease. Further study is required to confirm the validity of the Chapel Hill definitions, and especially to define the true relationship between classical PAN and MPA. There is also an urgent need for observations which will act as a surrogate for the defining histology to make application of the CHCC definitions more practicable. [7] 
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